Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report | Zendy

Alina Adeel | Zendy; Ming Qu | Zendy; Efaza Siddiqui | Zendy; Stuart M. Levitz | Zendy; Richard T. Ellison | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report

Author(s) -

Alina Adeel,

Ming Qu,

Efaza Siddiqui,

Stuart M. Levitz,

Richard T. Ellison

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab431

Subject(s) - medicine , candida glabrata , salvage therapy , intensive care medicine , antifungal , dermatology , chemotherapy

Rezafungin is a semi-synthetic, long acting echinocandin with broad spectrum activity against many Candida species (spp)., and Aspergillus spp., including subset of drug-resistant strains. It is currently in phase III trials and was found to be safe and effective for treatment of candidemia and/or invasive Candida infections in a phase II trial. However, there are no long-term safety or efficacy data. We report on the successful ongoing compassionate use of rezafungin obtained through expanded access for over one year in a patient with a multidrug-resistant Candida glabrata mediastinal infection from a vascular graft infection and retained foreign material.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research